COCP: Phase 2a Trial of CC-42344 Extended
On December 31, 2024, Cocrystal Pharma, Inc. (COCP) announced that the Phase 2a clinical trial of its oral PB2 inhibitor CC-42344 will be...
250 Views
COCP: Multiple Upcoming Catalysts
On November 13, 2024, Cocrystal Pharma, Inc. (COCP) announced financial results for the third quarter of 2024 and provided a business update. Over...
259 Views
COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24
On August 14, 2024, Cocrystal Pharma, Inc. (COCP) announced financial results for the second quarter of 2024 and provided a business update. In...
243 Views
COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated
On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of...
380 Views
COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344
On May 1, 2024, Cocrystal Pharma, Inc. (COCP) announced the completion of enrollment of 78 subjects in the randomized, double blind, placebo...
167 Views